The clinical features of MAS overlap with those of active sJIA, complicating early diagnosis and treatment. We evaluated adenosine deaminase 2 (ADA2), a protein of unknown function released ...

Collaboration Revenue: There was $2.3 million of collaboration revenue for the year ended December 31, 2024, as compared to no collaboration revenue for the year ended December 31, 2023. The increase ...

After hours: March 18 at 5:42:05 PM EDT Loading Chart for ROIV ...

Hyperuricemia (HU) is a metabolic disorder characterized by elevated uric acid (UA) levels in the bloodstream, commonly diagnosed when UA levels ...

KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

Add a description, image, and links to the deep-mutational-scanning topic page so that developers can more easily learn about it.

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...

Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expect ...

After hours: March 14 at 6:28:28 p.m. EDT Loading Chart for ROIV ...